SOURCE: Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc.

September 02, 2014 16:30 ET

Cleveland BioLabs to Report Outcome of July FDA Meeting and Host Conference Call on September 3

BUFFALO, NY--(Marketwired - Sep 2, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on September 3, 2014, it will report the outcome of the Company's July meeting with the U.S. Food and Drug Administration (FDA), and will host a conference call at 11:00 a.m. ET. 

Interested parties may participate by dialing 877-407-9205 (US) or 201-689-8054 (International), approximately five to ten minutes before the call start time. A live webcast of the conference call will be available on the Investors page of the Cleveland BioLabs web site at www.cbiolabs.com

A replay of the call will be available starting on September 3, 2014, at 2:00 p.m. ET through September 17, 2014, at 11:59 p.m. ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering conference ID number 13589652. An archived webcast of the conference call will be available for 90 days on the Investors page of the Cleveland BioLabs web site at www.cbiolabs.com.

About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are Entolimod, which is being developed as radiation countermeasure and a potential cancer treatment, and Curaxin CBL0137, our lead oncology product candidate. The company conducts business in the United States and in the Russian Federation through our three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.

Contact Information

  • Contact:
    Rachel Levine
    Vice President Investor Relations
    Cleveland BioLabs, Inc.
    T: (917) 375-2935
    E: rlevine@cbiolabs.com